Core Scientific (CORZ) Current Deferred Revenue (2021 - 2026)

Core Scientific has disclosed Current Deferred Revenue across 6 years of filings, most recently posting $654.2 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $654.2 million, up 974.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $654.2 million (up 974.26% YoY), and the FY2025 annual result was $555.9 million, up 2965.24% from the prior year.
• Current Deferred Revenue came in at $654.2 million for Q1 2026 at Core Scientific, up from $555.9 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $654.2 million in Q1 2026 to a low of $2.5 million in Q3 2025.
• The 5-year median for Current Deferred Revenue is $69.3 million (2022), against an average of $142.5 million.
• Across the five-year window, Current Deferred Revenue plunged 87.35% in 2023 and jumped 2965.24% in 2025, its largest moves.
• Core Scientific's Current Deferred Revenue stood at $77.7 million in 2022, then slumped by 87.35% to $9.8 million in 2023, then surged by 84.48% to $18.1 million in 2024, then surged by 2965.24% to $555.9 million in 2025, then rose by 17.7% to $654.2 million in 2026.
• The last three Current Deferred Revenue figures came in at $654.2 million (Q1 2026), $555.9 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.